Ghamari, Danial
Hauke, Philipp
Covino, Roberto
Faccioli, Pietro
Funding for this research was provided by:
European Research Council (Starting Grant: 804305)
State of Hesse Grant (Landes-Offensive zur Entwicklung Wissenschaftlich-Ökonomischer Exzellenz LOEWE CMMS)
CINECA (ISCRA-C)
Article History
Received: 28 April 2022
Accepted: 7 September 2022
First Online: 29 September 2022
Competing interests
: P.F. is co-founder of Sibylla Biotech SRL, a company exploiting molecular simulations to perform early stage drug discovery. The rest of authors declare no competing interest.